Sanofi Pasteur to provide funding support for Human Vaccines Project

Sanofi Pasteur has agreed a deal to partially fund the Human Vaccines Project, a not-for-profit public-private partnership bringing together academic researchers and industrial partners.

The global consortium is dedicated to solving primary problems impeding vaccine and immunotherapy development by decoding the human immune system, with Sanofi Pasteur's research funding to be used to help oversee, coordinate and conduct its scientific and administrative activities this year.

Specifically, the money will be used to to launch and execute pilot studies, build partnerships with and across the stakeholder community, and set up the infrastructure and operational support for the Human Vaccines Project Research Program.

As a member of the Project's industry advisory committee, Sanofi Pasteur will provide input on research programmes, review published and unpublished data, and participate in various scientific workshops.

Dr Jim Tartaglia, Sanofi Pasteur's research and development vice-president for new vaccine projects, said: "The Project's partnerships with industrial and non-profit product developers are key to ensuring that technological breakthroughs are rapidly translated into new products."

The Project has been endorsed as potentially transformative by 35 of the world's leading vaccine scientists and seeks to raise $1 billion (705.34 million pounds) over the course of a decade.